NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases |
|
|
| Recruiting | 2/3 | 75 | Europe, US, RoW | TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20. | Takeda, Takeda Development Center Americas, Inc. | Primary Immunodeficiency Diseases (PID) | 02/26 | 09/26 | | |
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks |
|
|
| Recruiting | N/A | 300 | Europe, RoW | rhC1INH or pdC1INH, Ruconest | Pharming Technologies B.V. | Hereditary Angioedema | 01/25 | 01/25 | | |
